Antidepressants and quality of life in patients with major depressive disorder – Systematic review and meta‐analysis of double‐blind, placebo‐controlled RCTs
Acta Psychiatrica Scandinavica · 2023-06 · 147 (6) · 545-560
DOI: 10.1111/acps.13541 ↗At a glance
Metaanalyse in Acta Psychiatrica Scandinavica, published online on 2023-03-20. Written by Teresa Wiesinger and 3 co-authors. Institution: Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Cologne, Cologne, Germany. Major MEDLINE topics: Major Depressive Disorder. Cited 26 times so far (Crossref); 84 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Quality of Life (QoL) is an important outcome in mental disorders. We investigated whether antidepressant pharmacotherapy improved QoL vs. placebo among patients with MDD.
Methods
Systematic literature search in CENTRAL, Medline, PubMed Central, and PsycINFO of double‐blind, placebo‐controlled RCTs. Screening, inclusion, extraction, and risk of bias assessment were conducted independently by two reviewers. We calculated summary standardized mean differences (SMD) with 95%‐CIs. We followed Cochrane Collaboration's Handbook of Systematic Reviews and Meta‐Analyses and PRISMA guidelines (protocol registration at OSF).
Results
We selected 46 RCTs out of 1807 titles and abstracts screened, including 16.171 patients, 9131 on antidepressants and 7040 on placebo, a mean age of 50.9 years, with 64.8% women. Antidepressant drug treatment resulted in a SMD in QoL of 0.22 ([95%‐CI: 0.18; 0.26] I 2 39%) vs. placebo. SMDs differed by indication: 0.38 ([0.29; 0.46] I 2 0%) in maintenance studies, 0.21 ([0.17; 0.25] I 2 11%) in acute treatment studies, and 0.11 ([−0.05; 0.26], I 2 51%) in studies focussing on patients with a physical condition and major depression. There was no indication of subtstantial small study effects, but 36 RCTs had a high or uncertain risk of bias, particularly maintenance trials. QoL and antidepressive effect sizes were associated (Spearman's rho 0.73, p < 0.001).
Conclusions
Antidepressants' effects on QoL are small in primary MDD, and doubtful in secondary major depression and maintenance trials. The strong correlation of QoL and antidepressive effects indicates that the current practice of measuring QoL may not provide sufficient additional insights into the well‐being of patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Cologne, Cologne, Germany.
- Department of Psychiatry and Psychotherapy, Technical University of Dresden, Dresden, Germany.
ORCID profiles: Christopher Baethge
Cite
APA
Wiesinger, T., Kremer, S., Bschor, T., & Baethge, C. (2023). Antidepressants and quality of life in patients with major depressive disorder – Systematic review and meta‐analysis of double‐blind, placebo‐controlled RCTs. Acta Psychiatrica Scandinavica, 147(6), 545-560. https://doi.org/10.1111/acps.13541
Vancouver
Wiesinger T, Kremer S, Bschor T, Baethge C. Antidepressants and quality of life in patients with major depressive disorder – Systematic review and meta‐analysis of double‐blind, placebo‐controlled RCTs. Acta Psychiatrica Scandinavica. 2023;147(6):545-560. doi:10.1111/acps.13541
BibTeX
@article{Wiesinger2023,
author = {Wiesinger, Teresa and Kremer, Stefanie and Bschor, Tom and Baethge, Christopher},
title = {Antidepressants and quality of life in patients with major depressive disorder – Systematic review and meta‐analysis of double‐blind, placebo‐controlled RCTs},
journal = {Acta Psychiatrica Scandinavica},
year = {2023},
volume = {147},
number = {6},
pages = {545--560},
doi = {10.1111/acps.13541}
}
EUVIMED